Literature DB >> 24333736

Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases.

Jong Hyun Lee1, Shu Yuan Chiang1, Dongwoo Nam1, Won-Seok Chung1, Junhee Lee1, Young-Soon Na2, Gautam Sethi3, Kwang Seok Ahn4.   

Abstract

Signal transducers and activators of transcription (STAT)-3 is a latent cytosolic transcription factor that has been closely associated with survival, proliferation, chemoresistance, and metastasis of tumor cells. Whether the anti-proliferative, pro-apoptotic, and anti-metastatic effects of capillarisin (CPS), derived from Artemisia capillaris (Compositae), are linked to its capability to inhibit STAT3 activation was investigated. We found that CPS specifically inhibited both constitutive and inducible STAT3 activation at tyrosine residue 705 but not at serine residue 727 in human multiple myeloma cells. Besides the inhibition of STAT3 phosphorylation, CPS also abrogated STAT3 constitutive activity and nuclear translocation. The suppression of STAT3 was mediated through the inhibition of activation of upstream JAK1, JAK2, and c-Src kinases. Treatment with the protein tyrosine phosphatase (PTP) inhibitor pervanadate treatment reversed the CPS-induced down-regulation of JAK1/2 and STAT3, thereby suggesting the involvement of a PTP. Indeed, knockdown of the SHP-1 and SHP-2 genes by small interfering RNA suppressed the ability of CPS to inhibit JAK1 and STAT3 activation, suggesting the critical role of both SHP-1 and SHP-2 in its possible mechanism of action. CPS downregulated the expression of STAT3-regulated antiapoptotic and proliferative gene products; and this correlated with suppression of cell viability, the accumulation of cells in sub-G1 phase of cell cycle and induction of apoptosis. Moreover, CPS potentiated bortezomib-induced apoptotic effects in MM cells, and this correlated with down-regulation of various gene products that mediate cell proliferation (Cyclin D1 and COX-2), cell survival (Bcl-2, Bcl-xl, IAP1, IAP2, and Survivin), invasion (MMP-9), and angiogenesis (VEGF). Thus, overall, our results suggest that CPS is a novel blocker of STAT3 activation and thus may have a potential in negative regulation of growth, metastasis, and chemoresistance of tumor cells.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Capillarisin; Multiple myeloma; PTP; STAT3

Mesh:

Substances:

Year:  2013        PMID: 24333736     DOI: 10.1016/j.canlet.2013.12.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  53 in total

1.  The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells.

Authors:  Ke-Hung Tsui; Ying-Ling Chang; Pei-Shan Yang; Chen-Pang Hou; Yu-Hsiang Lin; Bing-Wei Lin; Tsui-Hsia Feng; Horng-Heng Juang
Journal:  Cell Prolif       Date:  2017-12-21       Impact factor: 6.831

2.  Capillarisin Suppresses Lipopolysaccharide-Induced Inflammatory Mediators in BV2 Microglial Cells by Suppressing TLR4-Mediated NF-κB and MAPKs Signaling Pathway.

Authors:  Zhen Yu; Ling Tang; Lifen Chen; Jifang Li; Wanfu Wu; Changlin Hu
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

3.  Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.

Authors:  Asma Beldi-Ferchiou; Nour Skouri; Cyrine Ben Ali; Ines Safra; Abderrahman Abdelkefi; Saloua Ladeb; Karima Mrad; Tarek Ben Othman; Mélika Ben Ahmed
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

4.  53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.

Authors:  Shuhui Hong; Xiaoyan Li; Ying Zhao; Qifeng Yang; Beihua Kong
Journal:  Oncol Lett       Date:  2018-04-27       Impact factor: 2.967

5.  SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  L-C Fan; C-W Shiau; W-T Tai; M-H Hung; P-Y Chu; F-S Hsieh; H Lin; H-C Yu; K-F Chen
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

Review 6.  The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Authors:  Elina Khatoon; Mangala Hegde; Aviral Kumar; Uzini Devi Daimary; Gautam Sethi; Anupam Bishyaee; Ajaikumar B Kunnumakkara
Journal:  Arch Pharm Res       Date:  2022-08-20       Impact factor: 6.010

Review 7.  Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.

Authors:  Mitra Behroozaghdam; Maryam Dehghani; Amirhossein Zabolian; Davood Kamali; Salar Javanshir; Farzaneh Hasani Sadi; Mehrdad Hashemi; Teimour Tabari; Mohsen Rashidi; Sepideh Mirzaei; Atefeh Zarepour; Ali Zarrabi; Danielle De Greef; Anupam Bishayee
Journal:  Cell Mol Life Sci       Date:  2022-10-04       Impact factor: 9.207

8.  Epigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells.

Authors:  Moon Kyung Joo; Jong-Jae Park; Hyo Soon Yoo; Beom Jae Lee; Hoon Jai Chun; Sang Woo Lee; Young-Tae Bak
Journal:  Tumour Biol       Date:  2015-10-27

Review 9.  Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.

Authors:  Moon Kyung Joo; Jong-Jae Park; Hoon Jai Chun
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

10.  Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling.

Authors:  Xu Yang; Mei Huang; Qin Zhang; Jiao Chen; Juan Li; Qian Han; Lu Zhang; JiaQi Li; Shuai Liu; YuLan Ma; Lan Li; Lei Yang; SiYing Zou; Bin Han
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.